首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

市場調查報告書

商品編碼

1727695

癌症單株抗體的共同研究及授權契約:2016年～2025年

Cancer Monoclonal Antibody Collaboration and Licensing Deals 2016-2025

出版日期: 2025年05月01日 | 出版商:

Current Partnering | 英文 350+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

"癌症單株抗體合作與授權協議" 報告提供了全球領先生物製藥公司達成的癌症單株抗體交易的全面了解和前所未有的管道。

本報告詳細介紹了2016年至2025年癌症單株抗體交易，並詳細分析了該公司達成癌症單株抗體交易的方式和原因。這些交易通常包含多個要素，從合作研發到成果商業化。

本報告涵蓋了合作、開發、研究和授權交易。

本報告包含自2016年以來宣布的632項癌症單株抗體交易的完整列表，並包含交易方披露的實際癌症單株抗體合作交易的線上交易記錄連結。此外，如有公司及其合作夥伴向美國證券交易委員會提交的合約文件，報告也會記錄在案。

本報告第一章介紹了單株抗體 (MOA) 交易。

第一章是對報告的介紹。

第二章概述了自 2016 年以來單株抗體 (MOA) 交易的趨勢。

第三章概述了自 2016 年以來的主要單株抗體 (MOA) 交易。交易按總價值列出。

第四章提供了在單株抗體 (MOA) 交易中最活躍的 25 家公司的綜合列表，隨後是簡要摘要、單株抗體 (MOA) 交易的綜合列表以及公開的交易文件。

第五章全面深入地回顧了自2016年1月以來已完成或宣布的單株抗體 (MOA) 交易，並已公開交易文件。

第六章全面深入地回顧了自2016年1月以來已完成和宣布的所有單株抗體 (mAb) 合作交易。本章按感興趣的特定單株抗體 (mAb) 技術類型進行組織。

報告中還包含大量圖表和數據，顯示了自2016年以來單株抗體 (mAb) 交易的趨勢和活動。

此外，一份全面的交易目錄按公司 A-Z、交易類型和治療目標進行組織。每個交易標題都透過網頁連結連結到線上交易記錄以及合約文件（如有），以便輕鬆按需存取每個合約文件。

主要的優點

"癌症單株抗體合作與授權協議" （簡稱 "癌症單株抗體合作與授權協議" ）為讀者提供以下主要優勢：

了解自2016年以來的合約趨勢
瀏覽癌症單株抗體合作與授權交易
基準分析 - 確定交易的市場價值
財務條款 - 一次性付款、里程碑付款、特許權使用費
依公司A-Z、交易類型及治療領域排列的交易目錄
主要交易價值
最活躍的交易者
確定每筆交易的資產和交易條款
存取合約文件 - 深入了解交易結構
盡職調查 - 評估擬議交易條款是否適合您的合作夥伴公司
節省數百小時的研究時間

調查範圍

"腫瘤單株抗體合作與許可協議" 旨在深入了解世界領先生物製藥公司簽署的腫瘤單株抗體趨勢和交易結構。

"腫瘤單株抗體合作與授權協議" 包括：

生物製藥產業的腫瘤單株抗體交易趨勢
涵蓋製藥和生物技術領域的腫瘤單株抗體交易記錄目錄
主要的腫瘤單株抗體交易
最活躍的腫瘤單株抗體許可公司
"腫瘤單株抗體合作與授權協議" 提供全面的交易記錄，包括合約文件。

分析合約有助於進行以下方面的盡職調查：

授予或選擇的具體權利是什麼？
合約夥伴實際上被授予了什麼？
授予了哪些獨家權利？
合約的付款結構是怎樣的？
如何審計銷售和付款？
合約期限是多久？
合約的關鍵條款是如何界定的？
如何處理和歸屬知識產權？
誰負責商業化？
誰負責開發、供應和生產？
如何管理保密與揭露？
如何解決爭議？
在什麼情況下可以終止合約？
如果所有權發生變更會怎樣？
雙方約定了哪些分授權或分包條款？
公司堅持哪些樣板條款？
哪些樣板條款似乎因合作夥伴和交易類型而異？
公司在契約法方面主張哪些管轄權？

簡介
多年的癌症單株抗體交易
最活躍的癌症單株抗體交易業者
癌症單株抗體交易，各交易類型
癌症單株抗體交易，各治療領域
癌症單株抗體交易，各業界
癌症單株抗體交易的交易條件
- 癌症單株抗體交易的標題金額
- 癌症單株抗體交易預付款
- 癌症單株抗體交易的里程金
- 癌症單株抗體的特許權費用率

第3章 -主要癌症單株抗體交易

簡介
主要的癌症單株抗體交易，各金額

第4章 -最活躍的癌症單株抗體交易業者

簡介
最活躍的癌症單株抗體交易業者
最活躍的癌症單株抗體交易企業簡介

第5章 -癌症單株抗體契約交易名錄

簡介
癌症單株抗體契約交易名錄

第6章癌症單株抗體的各技術交易

交易名錄
交易名錄- 癌症單株抗體交易，各企業
交易名錄- 癌症單株抗體交易，各交易類型
交易名錄- 癌症單株抗體交易，各治療領域
交易類型定義
關於調查公司
目前聯盟
目前契約
最近的報告標題

簡介目錄

Product Code: CP22012

Cancer Monoclonal Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cancer monoclonal antibody deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of cancer monoclonal antibody deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter cancer monoclonal antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 632 cancer monoclonal antibody deals announced since 2016 including financial terms where available including links to online deal records of actual cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of cancer monoclonal antibody dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in cancer monoclonal antibody dealmaking since 2016.

Chapter 3 provides an overview of the leading cancer monoclonal antibody deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of cancer monoclonal antibody deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of cancer monoclonal antibody deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of cancer monoclonal antibody partnering deals signed and announced since Jan 2016. The chapter is organized by specific cancer monoclonal antibody technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in cancer monoclonal antibody deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Cancer Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2016
Browse cancer monoclonal antibody collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Cancer Monoclonal Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cancer monoclonal antibody trends and structure of deals entered into by leading biopharma companies worldwide.

Cancer Monoclonal Antibody Collaboration and Licensing Deals includes:

Trends in cancer monoclonal antibody dealmaking in the biopharma industry
Directory of cancer monoclonal antibody deal records covering pharmaceutical and biotechnology
The leading cancer monoclonal antibody deals by value
Most active cancer monoclonal antibody licensing dealmakers
Cancer Monoclonal Antibody Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cancer monoclonal antibody dealmaking

2.1. Introduction
2.2. Cancer monoclonal antibody deals over the years
2.3. Most active cancer monoclonal antibody dealmakers
2.4. Cancer monoclonal antibody deals by deal type
2.5. Cancer monoclonal antibody deals by therapy area
2.6. Cancer monoclonal antibody deals by industry sector
2.7. Deal terms for cancer monoclonal antibody deals
- 2.7.1 Cancer monoclonal antibody deals headline values
- 2.7.2 Cancer monoclonal antibody deal upfront payments
- 2.7.3 Cancer monoclonal antibody deal milestone payments
- 2.7.4 Cancer monoclonal antibody royalty rates